<DOC>
	<DOCNO>NCT00420680</DOCNO>
	<brief_summary>The purpose study evaluate safety 2.0 mg/kg 4.0 mg/kg sugammadex give reversal agent reappearance T2 0.6 mg/kg rocuronium cardiac patient</brief_summary>
	<brief_title>Safety Efficacy Evaluation Sugammadex Cardiac Patients ( 19.4.309 ) ( P05934 )</brief_title>
	<detailed_description />
	<criteria>Cardiac patient NYHA Class II III ASA class maximally 4 Age least 18 Scheduled elective , noncardiac surgery general anesthesia propofol supine position , plan muscle relaxation use rocuronium allow 12lead ECG assessment surgery ; Given write informed consent . Disorders interfere reliability assessment ( e.g . ECG measurement ) , paroxysmal atrial fibrillation presence pacemaker Known suspect neuromuscular disorder impair NMB Known suspect significant renal dysfunction Known suspect ( family ) history malignant hyperthermia Known suspect allergy narcotic , muscle relaxant medication use general anesthesia Intended ) use medication expect interfere effect rocuronium give trial , base dose and/or time administration ( antibiotic , anticonvulsant Mg2+ ) Pregnancy ( pregnancy exclude woman medical history hCG test within 24 h surgery , except woman childbearing potential , i.e . least 2 year menopausal undergone tubal ligation hysterectomy ) Childbearing potential without use method birth control use hormonal contraception birth control ( subject allow participate willing use condom , diaphragm spermicide , IUD , vasectomize partner ( &gt; 6 month ) abstinence , one month participation trial ) Breast feed Prior participation trial Org 25969 Participation another clinical trial pre approve Organon , within 30 day enter trial 19.4.309</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>